In lab studies, the orally active drug has been shown to degrade the VAV1 protein expressed in T- and B- cells. VAV1 is thought to be a signalling protein involved in the production of pro ...

Investigators sought to understand the safety and tolerability of MRT-6160, along with its ability to degrade a nucleotide exchange factor, VAV1. VAV1 plays a crucial role in several immune ...

MRT-6160 degrades a protein called VAV1. "Overall, we see this favorable collaboration agreement as additional robust validation of Monte Rosa's (platform) as well as acknowledgement of the ...

Wedbush raised the firm’s price target on Monte Rosa Therapeutics (GLUE) to $17 from $15 and keeps an Outperform rating on the shares after the ...

The company’s strong financial position was bolstered by a $150 million upfront payment from its recent licensing agreement with Novartis for VAV1 molecular glue degraders, including MRT-6160.